The modern-day study objectives at assessing the in-vitro usage of extracts of Echinacea to evaluate their inhibitory effect on pathogenic microorganisms (7 species) were isolated from different environments The methanolic crude extract of leaves of Echinacea purpurea were prepared using soxhlet apparatus. These extracts were examined to inhibited microbial strains like Pseudomonas aeruginosa, S. aureus, Klebsiella pneumonia, E. coli, Streptococcus epidermidis, Aspergillus niger, and C. albicans using the disc diffusion method. Methanol extract is more effective against resistance zone 14 mm against streptococcus. Against the MCF7 cell line, this percentage was increased after 48 hours. To consider the cytotoxic properties of herbal extract alongside human breast cancer (MCF7) cell lines with a concentration range of Echinacea purpurea extracts (6.25,12.5, 25,50,100,400 g/ml). With the maximum percentage increase resistance (97%) observed in treatment with 400mg / ml against the MCF7 cell line. The lowest ratios were discussed with MCF7 having a permanent cure (20%) at 12.5 mg/ml. Finally, GC mass analysis was performed for crude extracts to identify the most active chemical compounds of Echinacea purpurea extract, resulting in the existence of 26 biologically dynamic composites, including nine composites with antioxidant and anticancer activity.